ArticleJBMR plus2026
Measures of mortality among people living with fibrodysplasia ossificans progressiva in the United States, 2017-2023.
Article in JBMR plus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare genetic disease characterized by heterotopic ossification in connective tissues. Few epidemiologic studies have investigated mortality rates among people with FOP. We conducted a retrospective cohort study to understand mortality in people with FOP. Data were obtained from people with FOP in the United States (US) who participated in either the International FOP Association (IFOPA) membership database or the IFOPA patient registry between January 1, 2017, and December 31, 2023. From 2017 to 2023, 250 people with FOP were identified. The age-adjusted mortality rate was 34.6 (95% CI: 22.5-51.7) deaths per 1000 person-years. The annual age-adjusted mortality rate ranged from 21.0 (95% CI: 3.2-77.8) to 51.6 (95% CI: 19.1-114.7) deaths per 1000 person-years; the annual age-adjusted mortality rate ranged from 7.2 to 8.9 per 1000 person-years in the general US population. The median age at death for people with FOP was 50.5 (95% CI: 46.5-57.5) yr vs 80.5 yr in the general US population. The restricted mean time lost for people with FOP was 32.3 (95% CI: 26.8-37.8) yr vs 8.1 yr in the general US population. The US FOP population has substantial excess mortality vs the general US population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.